During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

When non-small cell lung cancer (NSCLC) spreads beyond the lungs, it often metastasizes to the bones. Estimates suggest 20 to 30 percent of people with NSCLC have bone metastases at the time of ...